CN102028938B - Medicament having effects of activating blood and dissolving stasis - Google Patents
Medicament having effects of activating blood and dissolving stasis Download PDFInfo
- Publication number
- CN102028938B CN102028938B CN 201010595545 CN201010595545A CN102028938B CN 102028938 B CN102028938 B CN 102028938B CN 201010595545 CN201010595545 CN 201010595545 CN 201010595545 A CN201010595545 A CN 201010595545A CN 102028938 B CN102028938 B CN 102028938B
- Authority
- CN
- China
- Prior art keywords
- medicine
- hirudin
- enteric coated
- mineral
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 210000004369 blood Anatomy 0.000 title abstract description 32
- 239000008280 blood Substances 0.000 title abstract description 30
- 230000000694 effects Effects 0.000 title abstract description 10
- 230000003213 activating effect Effects 0.000 title abstract description 4
- 102000007625 Hirudins Human genes 0.000 claims abstract description 50
- 108010007267 Hirudins Proteins 0.000 claims abstract description 50
- 229940006607 hirudin Drugs 0.000 claims abstract description 50
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 50
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 37
- 239000011707 mineral Substances 0.000 claims abstract description 37
- 150000001413 amino acids Chemical class 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000004615 ingredient Substances 0.000 claims description 39
- 238000009472 formulation Methods 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 27
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 25
- 206010008118 cerebral infarction Diseases 0.000 claims description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 18
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 18
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 18
- 239000004473 Threonine Substances 0.000 claims description 18
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 18
- 235000018417 cysteine Nutrition 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 18
- 229910052749 magnesium Inorganic materials 0.000 claims description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 16
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 16
- 239000011701 zinc Substances 0.000 claims description 16
- 229910052725 zinc Inorganic materials 0.000 claims description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 14
- 229910052804 chromium Inorganic materials 0.000 claims description 14
- 239000011651 chromium Substances 0.000 claims description 14
- 229910017052 cobalt Inorganic materials 0.000 claims description 14
- 239000010941 cobalt Substances 0.000 claims description 14
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 14
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 14
- 229960000310 isoleucine Drugs 0.000 claims description 14
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 12
- 235000003704 aspartic acid Nutrition 0.000 claims description 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 12
- 235000013922 glutamic acid Nutrition 0.000 claims description 12
- 239000004220 glutamic acid Substances 0.000 claims description 12
- 239000004474 valine Substances 0.000 claims description 12
- 201000006474 Brain Ischemia Diseases 0.000 claims description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 11
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 10
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 10
- 229910052711 selenium Inorganic materials 0.000 claims description 10
- 239000011669 selenium Substances 0.000 claims description 10
- 235000004400 serine Nutrition 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 8
- 229910052750 molybdenum Inorganic materials 0.000 claims description 8
- 239000011733 molybdenum Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 37
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 description 20
- 208000007536 Thrombosis Diseases 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 241000237903 Hirudo Species 0.000 description 16
- 239000002662 enteric coated tablet Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 8
- 229910052748 manganese Inorganic materials 0.000 description 8
- 239000011572 manganese Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940105567 molybdenum 0.5 mg Drugs 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229940087420 lysine 15 mg Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and discloses a medicament having the effects of activating blood and dissolving stasis. The medicament contains the following active ingredients: 0.1 to 100 weight parts of hirudin, 10 to 200 weight parts of amino acid and 0.05 to 10 weight parts of mineral substance. Through years of research, scientific researchers of the company, based on the modern medical theory, have found that a mixture of the hirudin, the amino acid and the mineral substance has good effects of activating blood and dissolving stasis. Pharmacological tests prove that the hirudin, the amino acid and the mineral substance have good synergistic effect and better pharmacological effect than the hirudin.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to the medicine that a kind of effective ingredient contains hirudin and has function of promoting blood circulation to disperse blood clots.
Background technology
Blood circulation promoting and blood stasis dispelling is meant that having dissipation role maybe can attack the method by blood stasis disease in the body.Activating blood and removing stasis drug has unobstructed blood vessels, and the dissipation stasis of blood stagnates, the effect of menstruction regulating and pain relieving, and its clinical scope of application is very wide, hinders uncomfortable in chest pained, the cyanotic lips due to the heart like the stasis of blood; The stasis of blood hinders the chest pain hemoptysis due to the lung; The stasis of blood hinders the hypochondriac pain mass in the abdomen due to the liver; The stasis of blood hinders the lower abdomen pain due to the uterus, menoxenia, dysmenorrhea etc.; The partial gall that the stasis of blood hinders due to the limbs is livid purple; The stasis of blood hinders hemiplegia due to the venation etc.
Hirudo, the popular name Hirudo records in the ancient medical book and utilizes Hirudo to treat multiple disease, call its " main by stagnant blood, blood stasis, month close, the removing blood stasis removing food stagnancy gathers ... ".Cure holy Zhang Zhongjing and use its eliminating pathogenic factor for supporting vital QI, the disease of treatment " blood stasis ", " water knot " has shown the curative effect that it is unique.Later age, Zhang Xichun praised this medicine: " deposit blood stasis and do not hinder fresh blood, the elite of pure lines water generates, and is at all harmless in edema caused by disorder of QI, and blood stasis is silently in invisible, and true good medicine also ".Before 1500 Christian eras, Egyptian's initiative Hirudo therapy of blood-letting, at the beginning of last century, the more superstitious Hirudo of European can suck the intravital sick blood of people, no matter headache and slight fever is generally suck the blood treatment with Hirudo.Along with the development of medical science, this Therapeutic Method that has superstitious color had just been abandoned gradually afterwards.Yet in recent years, Hirudo is just receiving people in medically new purposes and is paying close attention to widely.Plastic surgeon utilizes Hirudo to eliminate the blood stasis of operation back blood vessel block section, reduces downright bad the generation, thereby has improved the success rate of operations such as tissue transplantation and breast formation.When replanting or transplanting finger, toe, ear, nose, utilize Hirudo to suck blood, can make vein blood vessel unobstructed, improved the success rate of operation greatly, this is because Hirudo its salivary gland secretion anticoagulant hirudin when sucking blood, and the analogued histamine material of blood vessel dilating.1987, the cooperation of attached the 3rd hospital orthopedics of aquatic animal institute Hirudo seminar of the Chinese Academy of Sciences and Hubei medical science was at first used Hirudo treatment replantation of amputated finger postoperative blood stasis in China, successful numerical example, receive domestic, locate favorable comment widely.The various active material that contains in the Hirudo saliva is just receiving various countries scientist's extensive attention, has become a hot issue of resource animal use.U.S. Hirudo expert doctor Suo Ye in 1984 has founded the first in the world man hirudiniculture field biochemical drug company of holding concurrently in this west of British Wales; Hirudin and hyaluronidase that the said firm produces have been sold to European and American countries and Japan, and have also sold the Hementaria officianalis of tens thousand of work.Recently, built up another Hementaria officianalis plant of family in the Charleston of the U.S.; The gene transfer that France and Germany will synthesize hirudin and utilizes genetic engineering method to produce the hirudin of cheapness in yeast and escherichia coli.It is thus clear that the needs of hirudin and production enlarge.The low-molecular-weight that hirudin is made up of 65 aminoacid (7000) polypeptide, isoelectric point, IP lower (3.8～4.0), at room temperature steady in a long-term.Hirudin is the most effective known natural anticoagulant, and its effect is superior to heparin, has anticoagulation, thrombolytic effect, i.e. the said function of promoting blood circulation to disperse blood clots of the traditional Chinese medical science.Therefore, handling such as the deteriorated blood shock, atherosclerosis, cerebral infarction, cardiovascular diseases, hypertension, ophthalmology and the multiple disease aspect that lacks antithrombase demonstrate huge superiority and wide prospect.
Hirudo has good pharmacological action, and it has effect widely in clinical, but how to give full play to the excellent effect effect of Hirudo or hirudin, is one of research emphasis of a lot of medical workers.
Summary of the invention
For these reasons; The scientific research personnel of our company is through research for many years; With the modern medical theory is the basis, finds to have after hirudin and aminoacid, mineral make up the effect of good blood circulation promoting and blood stasis dispelling, and the present invention confirms through pharmacological testing; Hirudin and aminoacid, mineral have good synergism, have better pharmacological action than independent use hirudin.
The present invention realizes through following technical proposals.
A kind of medicine with function of promoting blood circulation to disperse blood clots, effective ingredient are hirudin, aminoacid and mineral, hirudin 0.1-100 weight portion wherein, amino acid/11 0-200 weight portion, mineral 0.05-10 weight portion.
Hirudin 0.5-80 weight portion wherein, aminoacid 20-100 weight portion, mineral 0.1-5 weight portion.
Wherein said aminoacid includes but not limited to following: in aspartic acid, glutamic acid, cysteine, serine, glycine, threonine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, histidine and the lysine one or more.
Its mineral includes but not limited to following: in calcium, magnesium, ferrum, zinc, manganese, selenium, cobalt, chromium, the molybdenum one or more.
Its Chinese medicine is oral formulations or ejection preparation.
Wherein oral formulations is an enteric coated preparation.
Wherein ejection preparation is aqueous injection, infusion solution or injectable powder.
Wherein enteric coated preparation is an enteric coated capsule.
Wherein enteric coated preparation is enteric coatel tablets.
Wherein enteric coated preparation is an enteric coated micropill.
One, pharmacological test example
Test 1
To the thrombotic influence of rat carotid artery
Experimental animal: Wistar rat, male and female dual-purpose, body weight 180～220g.
Trial drug:
Test 1 group: hirudin.
Test 2 groups: hirudin 0.1mg, winter propylhomoserin 2mg, glutamic acid 8mg, mineral calcium 0.03mg, magnesium 0.01mg, ferrum 0.01mg.
Test 3 groups: hirudin 100mg; Aminoacid 200mg (aspartic acid 10mg, glutamic acid 10mg, cysteine 10mg, serine 15mg, glycine 10mg, threonine 10mg, alanine 15mg, valine 15mg, leucine 25mg, isoleucine 15mg, proline 15mg, phenylalanine 10mg, tyrosine 15mg, histidine 15mg, lysine 10mg), mineral 10mg (calcium 1mg, magnesium 1mg, ferrum 3mg, zinc 0.55mg, manganese 1mg, selenium 0.95mg, cobalt 0.5mg, chromium 1mg, molybdenum 1mg).
Test 4 groups: hirudin 50mg; Amino acid/11 00mg (glutamic acid 15mg, cysteine 5mg, threonine 5mg, valine 15mg, isoleucine 15mg, proline 15mg, phenylalanine 15mg, histidine 15mg), mineral 4mg (calcium 2mg, magnesium 1mg, ferrum 0.5mg, molybdenum 0.5mg).
Test reagent: pentobarbital sodium.
Test apparatus: 16 lead the physiological signal acquisition analysis system.
Test method: with the rat random group: i.e. blank group, trial drug group.Dosage 1mg/kg.Every day, the coloclysis administration was 1 time, continuous 7d, and the blank group gives isopyknic distilled water.1h begins test after the last administration.Rat is under 2.5% pentobarbital sodium intraperitoneal injection of anesthesia, and it is fixing to lie on the back, and cuts skin of neck, separates the common carotid artery that the right side is about 1.5cm, and near tissue hiding with plastic paper avoids tissue temperature to the blood vessel Influence of Temperature.At tremulous pulse proximal part held stimulating electrode, the distal end held connects the conductor temperature probe of instrument, opens instrument switch, gives 2mA galvanic stimulation 7min with the damage arterial endothelial cell through stimulating electrode.Along with thrombosis in the arterial lumen forms gradually, blood flow is blocked gradually, and the temperature of arterial distal descends gradually.When blood flow is blocked fully, the temperature bust, instrument is reported to the police, and shows the arteries duration of congestion, promptly begins to TFT (surpassing 50min in 50min) from electricity irritation.
Result of the test: the result sees table 1.
The thrombotic influence of table 1 pair rat carotid artery
Annotate: compare * P＜0.05, * * P＜0.01 with the blank group; Compare △ P＜0.05 for 1 group with test.
Test the influence of 2 pairs of rat whole blood blood viscositys
Experimental animal: Wistar rat, male and female dual-purpose, body weight 180～220g.
Trial drug:
Test 1 group: hirudin.
Test 2 groups: hirudin 0.5mg, aspartic acid 20mg, mineral calcium 0.1mg.
Test 3 groups: hirudin 80mg; Amino acid/11 00mg (aspartic acid 5mg, glutamic acid 5mg, cysteine 3mg, serine 15mg, glycine 5mg, threonine 12mg, alanine 5mg, valine 5mg, leucine 15mg, isoleucine 5mg, proline 5mg, phenylalanine 1mg, tyrosine 13mg, histidine 1mg, lysine 5mg), mineral 5mg (magnesium 1mg, ferrum 1mg, zinc 0.51mg, manganese 0.99mg, cobalt 0.5mg, chromium 1mg).
Test 4 groups: hirudin 30mg; Aminoacid 55mg (cysteine 3mg, threonine 5mg, valine 15mg, proline 15mg, phenylalanine 12mg, histidine 5mg), mineral 1.8mg (zinc 0.53mg, selenium 0.45mg, cobalt 0.02mg, chromium 0.5mg, molybdenum 0.3mg).
Test apparatus: 16 lead the physiological signal acquisition analysis system; Tentative thrombus in vivo forms analyzer; The blood viscosity appearance.
Test method: with the rat random group: i.e. blank group, trial drug group.Dosage 1mg/kg.Every day, the coloclysis administration was 1 time, continuous 7d, and the blank group gives isopyknic distilled water.1h gets the blood 2mL adding anticoagulant tube from jugular sinus after the last administration, measures the whole blood blood viscosity.
Result of the test: the result sees table 2.
The influence of table 2 pair hemorheology of rat
Annotate: compare * P＜0.05, * * P＜0.01 with the blank group; Compare △ P＜0.05 for 1 group with test.
Test 3
Protective effect to rat cerebral infarction
Experimental animal: SD rat, 250-300g, male and female half and half.
Trial drug:
Test 1 group: hirudin.
Test 2 groups: hirudin 0.1mg, phenylalanine-3,4-quinone mg, tyrosine 2mg, histidine 5mg, mineral magnesium 0.03mg, ferrum 0.015, zinc 0.005mg.
Test 3 groups: hirudin 100mg; Aminoacid 200mg (aspartic acid 20mg, cysteine 10mg, serine 15mg, glycine 10mg, threonine 10mg, alanine 15mg, leucine 25mg, isoleucine 15mg, proline 15mg, phenylalanine 15mg, tyrosine 20mg, histidine 15mg, lysine 15mg), mineral 10mg (magnesium 2mg, ferrum 4mg, zinc 0.9mg, manganese 0.1mg, selenium 0.1mg, cobalt 0.9mg, chromium 0.5mg, molybdenum 1.5mg).
Test 4 groups: hirudin 60mg, aminoacid 80mg (glutamic acid 10mg, cysteine 15mg, threonine 5mg, isoleucine 25mg, proline 15mg, phenylalanine 10mg), mineral 5.5mg (calcium 3mg, magnesium 1mg, ferrum 1mg, molybdenum 0.5mg).
Test reagent: chloral hydrate; LNPT.
Test method: with the rat random packet: normal saline group, trial drug group.Dosage 1.5mg/kg.Every day, the coloclysis administration was 1 time, continuous 7d, and in the last administration after 30 minutes, chloral hydrate 300mg/kgip anesthetized rat; Cervical incision separates and the ligation right carotid, and behind the suture muscles skin, right lateral position is fixed; Cut skin at auris dextra and right eye outer canthus line mid point, separate temporalis, expose zygomatic process and temporal bone, open the bone window of about a 3 * 3mm at head end 1～2mm place of zygomatic process; Expose middle cerebral artery (MCA), it is disconnected that MCA is burnt, and sews up the incision.With reference to the administration of Bederson method, put to death animal, get right cerebral hemisphere, be cut into 5, place 37 ℃ of incubation 15min dyeing of 2g/LNPT, the white infarct cerebral tissue that carefully takes and weigh and do not dyed blue color.
Result of the test: the result sees table 3.
Table 3 pair rat cerebral infarction protection situation
Annotate: compare * * P＜0.01 with the normal saline group; Compare △ P＜0.05 for 1 group with test.
Test 4
Protective effect to acute cerebral ischemia in rats
Experimental animal: the SD rat, body weight 350 ± 47g, male and female are regardless of.
Trial drug:
Test 1 group: hirudin.
Test 2 groups: hirudin 0.5mg, proline 20mg, mineral ferrum 0.1mg.
Test 3 groups: hirudin 80mg; Amino acid/11 00mg (aspartic acid 15mg, cysteine 10mg, serine 8mg, glycine 5mg, threonine 2mg, alanine 15mg, leucine 25mg, isoleucine 20mg), mineral 5mg (magnesium 0.5mg, ferrum 1.5mg, zinc 0.5mg, manganese 0.5mg, cobalt 1mg, chromium 1mg).
Test 4 groups: hirudin 75mg, aminoacid 25mg (cysteine 5mg, threonine 5mg, valine 5mg, proline 5mg, histidine 5mg), mineral 4.5mg (calcium 3mg, zinc 0.5mg, selenium 0.45mg, cobalt 0.05mg, chromium 0.5mg).
Test reagent: pentobarbital sodium
Test method: with the rat random packet: normal saline group, trial drug group.Dosage 1.5mg/kg.Every day, the coloclysis administration was 1 time, and normal saline group etc. are held inequality, and administration began test in 2 hours.Acute imperfection cerebral ischemic model: rat pentobarbital sodium (40mg/kg) the ip anesthesia after the administration, the cervical region median incision, tracheal intubation is separated bilateral carotid, and dual ligation is also cut off, and 3h, 6h detect the variation of EEG after cerebral ischemia.Break end fast behind the 6h and get brain, change to detect brain water content and tectology.The change of EEG: the change according to document ischemic stage EEG is divided into 4 grades, the I level by its amplitude decline degree: no change, amplitude are more than 75% of former level; II level: the slight inhibition, be 50%～75% of former level; The III level: moderate suppresses, and is 25%～50% of former level; IV level: severe inhibition, 25% of flattened to former level.
The result sees table: the result sees table 4.
The protective effect of table 4 pair acute cerebral ischemia in rats
Annotate: compare * * P＜0.01 with the normal saline group; Compare △ P＜0.05 for 1 group with test.
Two, preparation embodiment
Embodiment 1
A kind of medicine with function of promoting blood circulation to disperse blood clots, effective ingredient are hirudin 0.1mg, winter propylhomoserin 2mg, glutamic acid 8mg, mineral calcium 0.03mg, magnesium 0.01mg, ferrum 0.01mg.
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 2
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 100mg; Aminoacid 200mg (aspartic acid 10mg, glutamic acid 10mg, cysteine 10mg, serine 15mg, glycine 10mg, threonine 10mg, alanine 15mg, valine 15mg, leucine 25mg, isoleucine 15mg, proline 15mg, phenylalanine 10mg, tyrosine 15mg, histidine 15mg, lysine 10mg), mineral 10mg (calcium 1mg, magnesium 1mg, ferrum 3.05mg, zinc 0.5mg, manganese 1mg, selenium 0.95mg, cobalt 0.5mg, chromium 1mg, molybdenum 1mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 3
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 50mg; Amino acid/11 00mg (glutamic acid 15mg, cysteine 5mg, threonine 5mg, valine 15mg, isoleucine 15mg, proline 15mg, phenylalanine 15mg, histidine 15mg), mineral 4mg (calcium 2mg, magnesium 1mg, ferrum 0.5mg, molybdenum 0.5mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 4
A kind of medicine with function of promoting blood circulation to disperse blood clots, effective ingredient are hirudin 0.5mg, aspartic acid 20mg, mineral calcium 0.1mg.
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 5
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 80mg; Amino acid/11 00mg (aspartic acid 5mg, glutamic acid 8mg, cysteine 3mg, serine 15mg, glycine 9mg, threonine 2mg, alanine 8mg, valine 5mg, leucine 5mg, isoleucine 5mg, proline 5mg, phenylalanine 2mg, tyrosine 13mg, histidine 3mg, lysine 12mg), mineral 5mg (magnesium 1mg, ferrum 1mg, zinc 0.5mg, manganese 0.99mg, cobalt 0.51mg, chromium 1mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 6
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 30mg; Aminoacid 55mg (cysteine 5mg, threonine 5mg, valine 15mg, proline 15mg, phenylalanine 10mg, histidine 5mg), mineral 1.8mg (zinc 0.5mg, selenium 0.48mg, cobalt 0.02mg, chromium 0.5mg, molybdenum 0.3mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 7
A kind of medicine with function of promoting blood circulation to disperse blood clots, effective ingredient are hirudin 0.5mg, proline 20mg, mineral ferrum 0.1mg.
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 8
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 80mg; Amino acid/11 00mg (aspartic acid 5mg, cysteine 10mg, serine 8mg, glycine 5mg, threonine 12mg, alanine 15mg, leucine 25mg, isoleucine 20mg), mineral 5mg (magnesium 0.5mg, ferrum 1.5mg, zinc 0.5mg, manganese 0.5mg, cobalt 1mg, chromium 1mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 9
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 75mg; Aminoacid 25mg (cysteine 5mg, threonine 5mg, valine 5mg, proline 5mg, histidine 5mg), mineral 4.5mg (calcium 3mg, zinc 0.5mg, selenium 0.45mg, cobalt 0.05mg, chromium 0.5mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 10
A kind of medicine with function of promoting blood circulation to disperse blood clots, effective ingredient are hirudin 0.1mg, phenylalanine-3,4-quinone mg, tyrosine 2mg, histidine 5mg, mineral magnesium 0.035mg, ferrum 0.01, zinc 0.005mg.
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 11
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 100mg; Aminoacid 200mg (aspartic acid 20mg, cysteine 10mg, serine 15mg, glycine 10mg, threonine 10mg, alanine 15mg, leucine 25mg, isoleucine 15mg, proline 15mg, phenylalanine 15mg, tyrosine 20mg, histidine 15mg, lysine 15mg), mineral 10mg (magnesium 2mg, ferrum 4mg, zinc 0.9mg, manganese 0.1mg, selenium 0.1mg, cobalt 0.9mg, chromium 1.5mg, molybdenum 1.5mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Embodiment 12
A kind of medicine with function of promoting blood circulation to disperse blood clots; Effective ingredient is hirudin 60mg; Aminoacid 80mg (glutamic acid 10mg, cysteine 15mg, threonine 5mg, isoleucine 25mg, proline 15mg, phenylalanine 10mg), mineral 5.5mg (calcium 3mg, magnesium 1mg, ferrum 1mg, molybdenum 0.5mg).
The said medicine effective ingredient is prepared into oral formulations; Oral formulations is enteric coated tablet, enteric coated capsule or enteric coated micropill.
Said medicine group effective ingredient is prepared into ejection preparation.
Claims (8)
1. medicine of treating cerebral infarction, cerebral ischemia; It is characterized in that effective ingredient is hirudin, aminoacid and mineral; Hirudin 0.1-100 weight portion wherein; Amino acid/11 0-200 weight portion; Mineral 0.05-10 weight portion, wherein aminoacid be in aspartic acid, glutamic acid, cysteine, serine, glycine, threonine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, histidine and the lysine one or more, its mineral be in calcium, magnesium, ferrum, zinc, manganese, selenium, cobalt, chromium, the molybdenum one or more.
2. a kind of medicine of treating cerebral infarction, cerebral ischemia according to claim 1, hirudin 0.5-80 weight portion wherein, aminoacid 20-100 weight portion, mineral 0.1-5 weight portion.
3. a kind of medicine of treating cerebral infarction, cerebral ischemia according to claim 1 and 2, its Chinese medicine is oral formulations or ejection preparation.
4. a kind of medicine of treating cerebral infarction, cerebral ischemia according to claim 3, wherein oral formulations is an enteric coated preparation.
5. a kind of medicine of treating cerebral infarction, cerebral ischemia according to claim 3, wherein ejection preparation is aqueous injection, infusion solution or injectable powder.
6. a kind of medicine of treating cerebral infarction, cerebral ischemia according to claim 4, wherein enteric coated preparation is an enteric coated capsule.
7. a kind of medicine of treating cerebral infarction, cerebral ischemia according to claim 4, wherein enteric coated preparation is enteric coatel tablets.
8. a kind of medicine of treating cerebral infarction, cerebral ischemia according to claim 4, wherein enteric coated preparation is an enteric coated micropill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010595545 CN102028938B (en) | 2010-12-20 | 2010-12-20 | Medicament having effects of activating blood and dissolving stasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010595545 CN102028938B (en) | 2010-12-20 | 2010-12-20 | Medicament having effects of activating blood and dissolving stasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102028938A CN102028938A (en) | 2011-04-27 |
| CN102028938B true CN102028938B (en) | 2012-12-05 |
Family
ID=43882751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010595545 Active CN102028938B (en) | 2010-12-20 | 2010-12-20 | Medicament having effects of activating blood and dissolving stasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102028938B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105617370A (en) * | 2016-01-28 | 2016-06-01 | 广州市当志强医药科技有限公司 | Hirudin blood stasis-removing paste and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911250A (en) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | Traditional Chinese medicine enteric oral liquor using leech extractive as active component, and its preparation method |
-
2010
- 2010-12-20 CN CN 201010595545 patent/CN102028938B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911250A (en) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | Traditional Chinese medicine enteric oral liquor using leech extractive as active component, and its preparation method |
Non-Patent Citations (6)
| Title |
|---|
| 侯倩等.《水蛭治疗脑梗塞相关研究近况》.《实用医药杂志》.2004,第21卷(第12期),第1134-1135页. * |
| 刘君.《蚂蝗抗凝血的活性成分研究》.《辽宁中医学院药学专业博士学位论文》.2005,第7-8页. * |
| 刘贞丽，潘继富，董传海.《水蛭的药理作用及其临床应用》.《时珍国医国药》.2002,第13卷(第6期),第376-377页. * |
| 李梅 等.《中药水蛭对血液流变学影响的临床研究》.《内蒙古中医药》.2008,(第1期),第9-10页. * |
| 潘贺，刚宏林，苏云明.《中药水蛭的活性成分及药理作用研究概况》.《中医药信息》.2006,第23卷(第1期),第20-21页. * |
| 程新法等.《水蛭的综合研究近况》.《中医文献杂志》.1997,(第3期),第44-45页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102028938A (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028938B (en) | Medicament having effects of activating blood and dissolving stasis | |
| CN102028939B (en) | Medicine with hirudin-containing active ingredient | |
| CN102078603B (en) | Medicine with action of treating cardiovascular and cerebrovascular diseases | |
| CN104147032A (en) | Drug composition for preventing and treating related diseases of ischemic stroke as well as preparation method and applications thereof | |
| US20240189382A1 (en) | Formula for inhibiting aging regeneration repair | |
| CN101332271A (en) | External medicine composition for treating burn and scald | |
| CN105412426A (en) | Traditional Chinese medicine for lowering blood pressure | |
| CN104147053A (en) | Oral liquid of traditional Uygur medicine named Kulumuti, and preparation method thereof | |
| CN1660345A (en) | Prepared Chinese medicine for treating burn and scald | |
| CN101347535A (en) | Regeneration plaster for burn and scald | |
| CN103989954A (en) | Traditional Chinese medicine preparation for treating iron-deficiency anemia | |
| CN109847024A (en) | A kind of Chinese medicine composition that treating insomnia and its navel paster of preparation | |
| CN103705504A (en) | Applications of Myrtucommuacetalone in medicines treating ischemic cerebral damage | |
| HUT66832A (en) | A stimulator of vascular endothelial cells and use thereof | |
| CN100431532C (en) | Breviscapine and borneol constituted composite injection formulation and preparation method thereof | |
| CN104623635B (en) | Pharmaceutical composition for preventing and treating cerebral ischemia | |
| CN106727873B (en) | Use of radix Hedysari or radix Hedysari polysaccharide for treating ischemic vascular diseases | |
| CN104758506A (en) | Traditional Chinese medicine for treating facial paralysis | |
| WO2017088177A1 (en) | Mussel adhesive protein product, and use thereof in preventing and suppressing neuronal inflammation | |
| Pandey et al. | The Scientific review on clinical and therapeutic aspects of Jalaukavacharan (leech therapy) | |
| CN109125308A (en) | Colchicin is in the new application for preventing and treating ischemic cerebrovascular disease | |
| CN105213841A (en) | For the ARR Chinese medicine composition of flaccidity of the heart-yang type | |
| Humphry | Centenarians: Miss Hastings, who died aged 104 | |
| CN108452297A (en) | The quickly Chinese medicine and preparation method thereof for the treatment of wart | |
| CN107638502A (en) | A kind of herbal mixture dripping pill for treating diabetes B and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant before: CHONGQING SHIZHENGE PUSHENG PHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING SHIZHEN'GE PUSHENG PHARMACEUTICAL CO., LTD. TO: CHONGQING DUOPUTAI PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Cao Jia Dian 400800 Chongqing city Wansheng District East Qingxi Bridge Patentee after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Patentee before: Chongqing Duoputai Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240118 Address after: No. 303-7, Qingxi Bridge, Donglin Street, Wansheng Economic Development Zone, Qijiang District, Chongqing, 400800 Patentee after: Chongqing Duoputai Pharmaceutical Technology Co.,Ltd. Address before: 400800 Donglin Qingxi bridge in Wansheng District, Chongqing Patentee before: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. |